209 related articles for article (PubMed ID: 25352401)
1. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Papadimitrakopoulou VA; Frank SJ; Cohen EW; Hirsch FR; Myers JN; Heymach JV; Lin H; Tran HT; Chen CR; Jimeno A; Nedzi L; Vasselli JR; Lowe ES; Raben D
Head Neck; 2016 Mar; 38(3):439-47. PubMed ID: 25352401
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Galloway TJ; Wirth LJ; Colevas AD; Gilbert J; Bauman JE; Saba NF; Raben D; Mehra R; Ma AW; Atoyan R; Wang J; Burtness B; Jimeno A
Clin Cancer Res; 2015 Apr; 21(7):1566-73. PubMed ID: 25573383
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Arias de la Vega F; Contreras J; de Las Heras M; de la Torre A; Arrazubi V; Herruzo I; Prieto I; García-Saenz JA; Romero J; Calvo FA;
Ann Oncol; 2012 Apr; 23(4):1005-9. PubMed ID: 21778302
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Eswaran P; Azmi KS
J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Gilbert J; Rudek MA; Higgins MJ; Zhao M; Bienvenu S; Tsottles N; Chaudhry MA; Wahl R; Forastiere A; Gillison M
Clin Cancer Res; 2012 Mar; 18(6):1735-42. PubMed ID: 22271880
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Mochimatu I; Ishitoya J; Kawai S; Mikami Y; Matsuda H; Tanigaki Y; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Hirose S; Sakuma Y; Yamamoto K
Br J Cancer; 2004 Jan; 90(2):348-52. PubMed ID: 14735175
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Le Tourneau C; Tao Y; Gomez-Roca C; Cristina V; Borcoman E; Deutsch E; Bahleda R; Calugaru V; Modesto A; Rouits E; Gollmer K; Vuagniaux G; Crompton P; Zanna C; Szyldergemajn S; Delord JP; Bourhis J
Clin Cancer Res; 2020 Dec; 26(24):6429-6436. PubMed ID: 32994295
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.
Fury MG; Lee NY; Sherman E; Ho AL; Rao S; Heguy A; Shen R; Korte S; Lisa D; Ganly I; Patel S; Wong RJ; Shaha A; Shah J; Haque S; Katabi N; Pfister DG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):479-86. PubMed ID: 24074921
[TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.
Van Waes C; Allen CT; Citrin D; Gius D; Colevas AD; Harold NA; Rudy S; Nottingham L; Muir C; Chen Z; Singh AK; Dancey J; Morris JC
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):447-54. PubMed ID: 19879702
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
16. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Mizumachi T; Homma A; Kakizaki T; Sakashita T; Kano S; Hatakeyama H; Tsuchiya K; Yasuda K; Onimaru R; Shirato H; Taguchi J; Shimizu Y; Kinoshita I; Akita H; Fukuda S
Int J Clin Oncol; 2015 Jun; 20(3):431-7. PubMed ID: 24993675
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
19. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
[TBL] [Abstract][Full Text] [Related]
20. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Rodriguez CP; Adelstein DJ; Rybicki LA; Saxton JP; Lorenz RR; Wood BG; Scharpf J; Ives DI
Head Neck; 2012 Nov; 34(11):1517-23. PubMed ID: 22180262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
